Overexpression of α (1,6) fucosyltransferase associated with aggressive prostate cancer

Glycobiology

Volumn 24, Issue 10, 2014, Pages 935-944

  Wang, Xiangchun ^a   Chen, Jing ^a   Li, Qing Kay ^a   Peskoe, Sarah B ^b   Zhang, Bai ^a   Choi, Caitlin ^a   Platz, Elizabeth A ^a,b   Zhang, Hui ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Aggressive prostate cancer; (1,6) fucosyltransferase

Indexed keywords

ALPHA (1,6) FUCOSYLTRANSFERASE; GLYCOSYLTRANSFERASE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; UVOMORULIN; FUCOSYLTRANSFERASE; GLYCOPROTEIN 6-ALPHA-L-FUCOSYLTRANSFERASE; POLYSACCHARIDE;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CELL MOTILITY; CONTROLLED STUDY; ENZYME GLYCOSYLATION; GENE OVEREXPRESSION; GENE SILENCING; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; LNCAP CELL LINE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN DEPLETION; PROTEIN EXPRESSION; RNA INTERFERENCE; TISSUE MICROARRAY; BIOSYNTHESIS; CANCER GRADING; CASTRATION RESISTANT PROSTATE CANCER; CELL MOTION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL MOVEMENT; FUCOSYLTRANSFERASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM GRADING; POLYSACCHARIDES; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84964313411     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwu051     Document Type: Article

References (44)

1. Baldi E, Bonaccorsi L, Forti G. 2003. Androgen receptor: Good guy or bad guy in prostate cancer invasion? Endocrinology. 144:1653-1655.
2. Burchell J, Poulsom R, Hanby A, Whitehouse C, Cooper L, Clausen H, Miles D, Taylor-Papadimitriou J. 1999. An alpha2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas. Glycobiology. 9:1307-1311.
3. Chen CY, Jan YH, Juan YH, Yang CJ, Huang MS, Yu CJ, Yang PC, Hsiao M, Hsu TL, Wong CH. 2013. Fucosyltransferase 8 as a functional regulator of nonsmall cell lung cancer. Proc Natl Acad Sci USA. 110:630-635.
4. Chiricolo M, Malagolini N, Bonfiglioli S, Dall'Olio F. 2006. Phenotypic changes induced by expression of beta-galactoside alpha2,6 sialyltransferase I in the human colon cancer cell line SW948. Glycobiology. 16:146-154.
5. de Leoz ML, An HJ, Kronewitter S, Kim J, Beecroft S, Vinall R, Miyamoto S, de Vere White R, Lam KS, Lebrilla C. 2008. Glycomic approach for potential biomarkers on prostate cancer: Profiling of N-linked glycans in human sera and pRNS cell lines. Dis Markers. 25:243-258.
6. Dube DH, Bertozzi CR. 2005. Glycans in cancer and inflammation - Potential for therapeutics and diagnostics. Nat Rev Drug Discov. 4:477-488.
7. Fujimura T, Shinohara Y, Tissot B, Pang PC, Kurogochi M, Saito S, Arai Y, Sadilek M, Murayama K, Dell A, et al. 2008. Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects. Int J Cancer. 122:39-49.
8. Granovsky M, Fata J, Pawling J, Muller WJ, Khokha R, Dennis JW. 2000. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat Med. 6:306-312.
9. Hakomori S. 1996. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 56:5309-5318.
10. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, et al. 1980. The LNCaP cell line - A new model for studies on human prostatic carcinoma. Prog Clin Biol Res. 37:115-132.
11. Ito Y, Miyauchi A, Yoshida H, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, et al. 2003. Expression of alpha1,6-fucosyltransferase (FUT8) in papillary carcinoma of the thyroid: Its linkage to biological aggressiveness and anaplastic transformation. Cancer Lett. 200:167-172.
12. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. 1979. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 17:16-23.
13. Kaku H, Goldstein IJ, Oscarson S. 1991. Interactions of five D-mannose-specific lectins with a series of synthetic branched trisaccharides. Carbohydrate Res. 213:109-116.
14. Kornfeld K, Reitman ML, Kornfeld R. 1981. The carbohydrate-binding specificity of pea and lentil lectins. Fucose is an important determinant. J Biol Chem. 256:6633-6640.
15. Kosanovic MM, Jankovic MM. 2005. Sialylation and fucosylation of cancerassociated prostate specific antigen. J Buon. 10:247-250.
16. Kyselova Z, Mechref Y, Kang P, Goetz JA, Dobrolecki LE, Sledge GW, Schnaper L, Hickey RJ, Malkas LH, Novotny MV. 2008. Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. Clin Chem. 54:1166-1175.
17. Li W, Liu Q, Pang Y, Jin J, Wang H, Cao H, Li Z, Wang X, Ma B, Chi Y, et al. 2012. Core fucosylation of mu heavy chains regulates assembly and intracellular signaling of precursor B cell receptors. J Biol Chem. 287: 2500-2508.
18. Li Y, Tian Y, Rezai T, Prakash A, Lopez MF, Chan DW, Zhang H. 2011. Simultaneous analysis of glycosylated and sialylated prostate-specific antigen revealing differential distribution of glycosylated prostate-specific antigen isoforms in prostate cancer tissues. Anal Chem. 83:240-245.
19. Liu YC, Yen HY, Chen CY, Chen CH, Cheng PF, Juan YH, Chen CH, Khoo KH, Yu CJ, Yang PC, et al. 2011. Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. Proc Natl Acad Sci USA. 108:11332-11337.
20. Markert EK, Mizuno H, Vazquez A, Levine AJ. 2011. Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci USA. 108:21276-21281.
21. Matsumura K, Higashida K, Ishida H, Hata Y, Yamamoto K, Shigeta M, Mizuno-Horikawa Y, Wang X, Miyoshi E, Gu J, et al. 2007. Carbohydrate binding specificity of a fucose-specific lectin from Aspergillus oryzae: A novel probe for core fucose. J Biol Chem. 282:15700-15708.
22. Miyoshi E, Shinzaki S, Moriwaki K, Matsumoto H. 2010. Identification of fucosylated haptoglobin as a novel tumor marker for pancreatic cancer and its possible application for a clinical diagnostic test. Methods Enzymol. 478:153-164.
23. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. 1995. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 154:407-413.
24. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, et al. 1997. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res. 3:2493-2500.
25. Ohtsubo K, Marth JD. 2006. Glycosylation in cellular mechanisms of health and disease. Cell. 126:855-867.
26. Pascal LE, Vencio RZ, Page LS, Liebeskind ES, Shadle CP, Troisch P, Marzolf B, True LD, Hood LE, Liu AY. 2009. Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes. BMC Cancer. 9:452.
27. Saldova R, Fan Y, Fitzpatrick JM, Watson RW, Rudd PM. 2011. Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology. 21:195-205.
28. Sato Y, Nakata K, Kato Y, Shima M, Ishii N, Koji T, Taketa K, Endo Y, Nagataki S. 1993. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med. 328:1802-1806.
29. Schroder FH. 2011. Stratifying risk - The U.S. Preventive Services Task Force and prostate-cancer screening. N Engl J Med. 365:1953-1955.
30. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, et al. 2009. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 360:1320-1328.
31. Seales EC, Jurado GA, Brunson BA, Wakefield JK, Frost AR, Bellis SL. 2005. Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. Cancer Res. 65:4645-4652.
32. Sensibar JA, Sutkowski DM, Raffo A, Buttyan R, Griswold MD, Sylvester SR, Kozlowski JM, Lee C. 1995. Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res. 55:2431-2437.
33. Sewell R, Backstrom M, Dalziel M, Gschmeissner S, Karlsson H, Noll T, Gatgens J, Clausen H, Hansson GC, Burchell J, et al. 2006. The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer. J Biol Chem. 281:3586-3594.
34. Sherwood ER, Pitt Ford TR, Lee C, Kozlowski JM. 1990. Therapeutic efficacy of recombinant tumor necrosis factor alpha in an experimental model of human prostatic carcinoma. J Biol Response Modif. 9:44-52.
35. Siegel R, Naishadham D, Jemal A. 2013. Cancer statistics, 2013. CA. 63:11-30.
36. Swindall AF, Bellis SL. 2011. Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells. J Biol Chem. 286:22982-22990.
37. Taniguchi N, Miyoshi E, Gu J, Honke K, Matsumoto A. 2006. Decoding sugar functions by identifying target glycoproteins. Curr Opin Struct Biol. 16:561-566.
38. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, et al. 2004. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 350:2239-2246.
39. Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, Walsh PC, Carter HB. 2011. Active surveillance program for prostate cancer: An update of the Johns Hopkins experience. J Clin Oncol. 29:2185-2190.
40. van Roy F, Berx G. 2008. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci. 65:3756-3788.
41. Wang X, Gu J, Ihara H, Miyoshi E, Honke K, Taniguchi N. 2006. Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling. J Biol Chem. 281:2572-2577.
42. Wang X, Inoue S, Gu J, Miyoshi E, Noda K, Li W, Mizuno-Horikawa Y, Nakano M, Asahi M, Takahashi M, et al. 2005. Dysregulation of TGF-beta1 receptor activation leads to abnormal lung development and emphysema-like phenotype in core fucose-deficient mice. Proc Natl Acad Sci USA. 102: 15791-15796.
43. Yoshimura M, Nishikawa A, Ihara Y, Taniguchi S, Taniguchi N. 1995. Suppression of lung metastasis of B16 mouse melanoma by N-acetylglucosaminyltransferase III gene transfection. Proc Natl Acad Sci USA. 92:8754-8758.
44. Zhao Y, Itoh S, Wang X, Isaji T, Miyoshi E, Kariya Y, Miyazaki K, Kawasaki N, Taniguchi N, Gu J. 2006. Deletion of core fucosylation on alpha3beta1 integrin down-regulates its functions. J Biol Chem. 281:38343-38350.